AU2005271372B2 - Optimizing expression of active botulinum toxin type A - Google Patents

Optimizing expression of active botulinum toxin type A Download PDF

Info

Publication number
AU2005271372B2
AU2005271372B2 AU2005271372A AU2005271372A AU2005271372B2 AU 2005271372 B2 AU2005271372 B2 AU 2005271372B2 AU 2005271372 A AU2005271372 A AU 2005271372A AU 2005271372 A AU2005271372 A AU 2005271372A AU 2005271372 B2 AU2005271372 B2 AU 2005271372B2
Authority
AU
Australia
Prior art keywords
seq
cell
open reading
reading frame
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005271372A
Other languages
English (en)
Other versions
AU2005271372A1 (en
Inventor
Kei Roger Aoki
Ester E. Fernandez-Salas
Marcella A. Gilmore
Shengwen Li
Ronald G. Miller
Iance E. Steward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35355531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005271372(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2005271372A1 publication Critical patent/AU2005271372A1/en
Application granted granted Critical
Publication of AU2005271372B2 publication Critical patent/AU2005271372B2/en
Priority to AU2012211346A priority Critical patent/AU2012211346A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2005271372A 2004-08-04 2005-08-03 Optimizing expression of active botulinum toxin type A Ceased AU2005271372B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012211346A AU2012211346A1 (en) 2004-08-04 2012-08-03 Optimizing expression of active botulinum toxin type A

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59912104P 2004-08-04 2004-08-04
US60/599,121 2004-08-04
PCT/US2005/027917 WO2006017749A2 (en) 2004-08-04 2005-08-03 Optimizing expression of active botulinum toxin type a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012211346A Division AU2012211346A1 (en) 2004-08-04 2012-08-03 Optimizing expression of active botulinum toxin type A

Publications (2)

Publication Number Publication Date
AU2005271372A1 AU2005271372A1 (en) 2006-02-16
AU2005271372B2 true AU2005271372B2 (en) 2012-05-03

Family

ID=35355531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005271372A Ceased AU2005271372B2 (en) 2004-08-04 2005-08-03 Optimizing expression of active botulinum toxin type A

Country Status (6)

Country Link
US (2) US20080057575A1 (enExample)
EP (1) EP1773874B1 (enExample)
JP (1) JP2008508886A (enExample)
AU (1) AU2005271372B2 (enExample)
CA (1) CA2575994A1 (enExample)
WO (1) WO2006017749A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006017749A2 (en) * 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
JP4994241B2 (ja) 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
KR20090018799A (ko) * 2006-05-30 2009-02-23 다우 글로벌 테크놀로지스 인크. 코돈 최적화 방법
EP2167119B1 (en) 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
AU2009339292B2 (en) 2008-12-10 2016-01-21 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP2218783A1 (en) 2009-02-05 2010-08-18 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of neurotoxins
JP5826635B2 (ja) 2009-03-13 2015-12-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系調節エンドペプチターゼ活性アッセイ
JP2013514091A (ja) 2009-12-16 2013-04-25 アラーガン、インコーポレイテッド 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素
US8980284B2 (en) * 2010-01-25 2015-03-17 New York University Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
SI2528940T1 (sl) 2010-01-25 2014-07-31 Allergan, Inc. Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
CA2816217C (en) 2010-11-23 2014-07-29 Allergan, Inc. Compositions and methods of producing enterokinase in yeast
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
AU2012255746B2 (en) * 2011-05-17 2016-04-28 Boston Scientific Neuromodulation Corporation User-defined graphical shapes used as a visualization aid for stimulator programming
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
EP2793934B1 (en) 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
US9732123B2 (en) 2013-03-15 2017-08-15 The Trustees Of The University Of Pennsylvania Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of Clostridium botulinum
EP3113792B1 (en) 2014-03-05 2018-12-05 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
KR102514666B1 (ko) 2014-12-19 2023-03-27 메르츠 파마 게엠베하 운트 코. 카가아 세포에서 BoNT/E의 생물학적 활성의 결정을 위한 수단 및 방법
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
ES2929347T3 (es) 2016-01-20 2022-11-28 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
MX395130B (es) 2016-03-02 2025-03-24 Merz Pharma Gmbh & Co Kgaa Composicion que comprende toxina botulinica
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
EP3642222A1 (en) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
WO2019081022A1 (en) 2017-10-26 2019-05-02 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
EP3713595A1 (en) 2017-11-22 2020-09-30 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
KR20200115584A (ko) * 2018-01-30 2020-10-07 칠드런'즈 메디컬 센터 코포레이션 바실루스 시스템을 이용한 보툴리눔 신경독소의 생산
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US11959069B2 (en) * 2019-02-28 2024-04-16 Proteonic Biotechnology Ip B.V. Self-immolative plasmid backbone
WO2022197623A1 (en) * 2021-03-15 2022-09-22 Children's Medical Center Corporation Engineered botulinum neurotoxin a protease domain with improved efficacy
GB202104294D0 (en) * 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030009025A1 (en) * 1993-09-21 2003-01-09 Smith Leonard A. Recombinant vaccine against botulinum neurotoxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
UA48104C2 (uk) * 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
WO2000067700A2 (en) * 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Recombinant vaccine against botulinum neurotoxin
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
JP2002514886A (ja) * 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EP1020517A4 (en) * 1997-07-11 2004-11-17 Chugai Pharmaceutical Co Ltd Gene originating in human chondrocyte
US6277622B1 (en) * 1997-08-11 2001-08-21 The University Of Sydney Synthetic polynucleotides
US6218188B1 (en) * 1997-11-12 2001-04-17 Mycogen Corporation Plant-optimized genes encoding pesticidal toxins
US6214602B1 (en) * 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AU2002211490A1 (en) * 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
TW200403338A (en) * 2002-07-16 2004-03-01 Advisys Inc Codon optimized synthetic plasmids
WO2006017749A2 (en) * 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030009025A1 (en) * 1993-09-21 2003-01-09 Smith Leonard A. Recombinant vaccine against botulinum neurotoxin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SMITH, L.A. et al, Movement Disorders, 2004, Vol. 19, Suppl. 8, S48-S52 *
SMITH, L.A., Toxicon, 1998, Vol. 36, pages 1539-1548 *

Also Published As

Publication number Publication date
AU2005271372A1 (en) 2006-02-16
US20090023198A1 (en) 2009-01-22
WO2006017749A3 (en) 2006-03-30
US20080057575A1 (en) 2008-03-06
JP2008508886A (ja) 2008-03-27
WO2006017749A2 (en) 2006-02-16
CA2575994A1 (en) 2006-02-16
EP1773874A2 (en) 2007-04-18
EP1773874B1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
EP1773874B1 (en) Optimizing expression of active botulinum toxin type a
US7825233B2 (en) Optimizing expression of active Botulinum Toxin type E
EP2178905B1 (en) Methods of activiting clostridial toxins
EP2154151B1 (en) Clostridial toxin activatable clostridial toxins
AU2005279741B2 (en) Degradable clostridial toxins
CA2657521A1 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008803A2 (en) Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
SG182691A1 (en) Methods of intracellular conversion of single-chain proteins into their di-chain form
CA2784666A1 (en) Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
EP2001902B1 (en) Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20110111483A1 (en) Optimizing Expression of Active Botulinum Toxin Type E
US20130288336A1 (en) Methods of activating clostridial toxins
AU2012211346A1 (en) Optimizing expression of active botulinum toxin type A
AU2013204638A1 (en) Optimizing expression of active botulinum toxin type A

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired